BioAlliance Pharma acquired European rights for Ondansetron OS
                   
marketwire.com     May 20, 2008            

PARIS--(Marketwire - May 20, 2008) - BioAlliance acquired European rights for Ondansetron oral spray to complement its franchise in cancer supportive care from NovaDel Pharma Inc. Paris, May 20, 2008 - BioAlliance Pharma SA (Euronext Paris - BIO) a specialty pharmaceutical company focused on the... [read full story]                    


View all news articles about*:
Cancer Cancers Care Euronext France Gastrointestinal Health Ile-de-France Infections Marketwire Nausea Oncology Paris Patients Pharmaceuticals Symptoms Therapy Vomiting
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies

View other selected articles:

                   

Duodenal Derotation As an Effective Treatment of Superior Mesenteric Artery Syndrome: A...

redorbit.com     yesterday          

Posted on: Friday, 29 August 2008, 03:00 CDT By Ha, Chi D Alvear, Domingo T; Leber, David C We evaluated the use of duodenal derotation as a surgical option for superior mesenteric artery syndrome (SMAS) in two groups of...                    

comments

                   

How Do You Treat Invasive Salmonella Infections?

pediatriceducation.org     Aug 27, 2008          

Patient Presentation A 16-year-old female came to the emergency room with a 36 hour history of diarrhea and emesis. She had been on a school trip in Europe and during the day she was leaving to return to the United States...                    

comments

                   

100 Struck Down By Norovirus in Resort ; More Than 100 People in a Seaside Resort Have Been...

redorbit.com     Aug 22, 2008          

By Jane Omara More than 100 people in a seaside resort have been struck down by a fast-spreading stomach bug that causes vomiting and diarrhoea. The bug, which tests have confirmed as norovirus, first broke out in Mawgan Porth,...                    

comments

                   

FDA Grants IND For Pro-Pharmaceuticals' DAVANAT® To Treat Breast Cancer Patient

medicalnewstoday.com     25 mins ago   4 related          

Pro-Pharmaceuticals, Inc. (Amex: PRW), today announced that the U.S. Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) application for use of DAVANAT® in combination with 5-FU to treat a...                    

comments